nach oben

Erschienen in:

01.01.2025 | Case Based Review

New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review

verfasst von: Sophie Mavrogeni, Evdoxia Sapountzi, Kyveli Chiotopoulou, Lampros Fotis

Erschienen in: Rheumatology International | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Abstract

The safety of tumor necrosis factor (TNF) inhibitors has been demonstrated for over two decades. However, their effects on cardiovascular function in patients with rheumatic diseases remain controversial, and conclusions are additionally hampered by the cardiovascular complications inherent in such diseases. We present two 15-year-old patients diagnosed with ankylosing spondylitis and juvenile idiopathic arthritis classified as polyarthritis with positive rheumatoid factor, respectively. Soon after treatment onset with adalimumab and etanercept, respectively, they developed myocardial inflammation leading to heart failure. Their condition improved upon treatment discontinuation and onset of secukinumab and tocilizumab, respectively. A thorough literature search revealed that these are the only cases of heart failure reported to date after anti-TNF treatment in adolescents with rheumatic diseases. Although cardiovascular adverse effects seem to be very rare in this population, even atypical symptoms of cardiac failure should not be ignored, and cardiac function should be closely monitored when administering anti-TNF-α.

Nur mit Berechtigung zugänglich

Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP (2022) The second decade of anti-TNF-α therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 42(9):1493–1511. https://doi.org/10.1007/s00296-022-05136-xCrossRefPubMedPubMedCentral

Ntusi NAB, Francis JM, Sever E, Liu A, Piechnik SK, Ferreira VM, Matthews PM, Robson MD, Wordsworth PB, Neubauer S, Karamitsos TD (2018) Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol 270:253–259CrossRefPubMed

Toufaily A (2020) Severe cardiomyopathy induced by Adalimumab administration for Crohn’s disease. J Cardio Case Rep 3. https://doi.org/10.15761/JCCR.1000129

Grillo TG, Silveira CFDSMP, Quaglio AEV, Dutra RM, Baima JP, Bazan SGZ, Sassaki L (2023) Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature. World J Cardiol 15(5):217–228. https://doi.org/10.4330/wjc.v15.i5.217CrossRefPubMedPubMedCentral

Coulson EJ, Ng WF, Goff I, Foster HE (2013) Cardiovascular risk in juvenile idiopathic arthritis. Rheumatology (Oxford) 52(7):1163–1171. https://doi.org/10.1093/rheumatology/ket106CrossRefPubMed

Page RL 2nd, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, American heart association clinical pharmacology and heart failure and transplantation committees of the council on clinical cardiology; council on cardiovascular surgery and anesthesia; council on cardiovascular and stroke nursing; and council on quality of care and outcomes research (2016) Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134(6):e32-69. https://doi.org/10.1161/CIR.0000000000000426. Erratum in: Circulation. 2016;134(12):e261. https://doi.org/10.1161/CIR.0000000000000449

Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J (2019) 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol 71(6):846–863. https://doi.org/10.1002/art.40884CrossRefPubMedPubMedCentral

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

Atzeni F, Nucera V, Galloway J, Zoltán S, Nurmohamed M (2020) Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opin Biol Ther 20(5):517–524. https://doi.org/10.1080/14712598.2020.1704727CrossRefPubMed

10.

Gruca M, Orczyk K, Zamojska J, Niewiadomska-Jarosik K, Stańczyk J, Smolewska E (2023) Why and how should we assess the cardiovascular risk in patients with juvenile idiopathic arthritis? A single-centre experience with carotid intima-media measurements. Child (Basel) 10(3):422. https://doi.org/10.3390/children10030422CrossRef

11.

Schumacher SM, Naga Prasad SV (2018) Tumor necrosis factor-α in heart failure: an updated review. Curr Cardiol Rep 20(11):117. https://doi.org/10.1007/s11886-018-1067-7CrossRefPubMedPubMedCentral

12.

Sinagra E, Perricone G, Romano C, Cottone M (2013) Heart failure and anti-tumor necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Intern Med 24(5):385–392. https://doi.org/10.1016/j.ejim.2012.12.015CrossRefPubMed

13.

Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138(10):807–811. https://doi.org/10.7326/0003-4819-138-10-200305200-00008CrossRefPubMed

14.

Castro Rocha FA, Silva FS Jr (2010) Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis. J Clin Rheumatol 16(2):81–82. https://doi.org/10.1097/RHU.0b013e3181d06f5b

15.

Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116(5):305–311. https://doi.org/10.1016/j.amjmed.2003.09.039CrossRefPubMed

16.

Kotyla PJ (2018) Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci 19(6):1739. https://doi.org/10.3390/ijms19061739CrossRefPubMedPubMedCentral

17.

Cole J, Busti A, Kazi S (2007) The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 27(4):369–373. https://doi.org/10.1007/s00296-006-0215-3CrossRefPubMed

18.

Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW (2007) A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 46(7):1122–1125. https://doi.org/10.1093/rheumatology/kem033CrossRefPubMed

19.

Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, ARTIS Group (2005) Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64(2):246–252. https://doi.org/10.1136/ard.2004.023473CrossRefPubMed

20.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272–2283. https://doi.org/10.1002/art.24638CrossRefPubMed

21.

Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846. https://doi.org/10.1111/j.1749-6632.2009.04621.xCrossRefPubMed

22.

Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM (2017) Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol 31(1):89–95. https://doi.org/10.1111/jdv.13746CrossRefPubMed

23.

Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71(11):1788–1800. https://doi.org/10.1002/art.41032CrossRefPubMed

24.

Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, Swierkot J, Khan N, Bu X, Li Y, Song IH (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 8(1). https://doi.org/10.1136/rmdopen-2021-002012

25.

Blair HA, Secukinumab (2019) A review in ankylosing spondylitis. Drugs 79(4):433–443CrossRefPubMedPubMedCentral

26.

von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T (2019) Impact of Secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139(5):1054–1062CrossRef

27.

Makavos G, Ikonomidis I, Andreadou I, Varoudi M, Kapniari I, Loukeri E, Theodoropoulos K, Pavlidis G, Triantafyllidi H, Thymis J, Parissis J, Tsoumani M, Rafouli-Stergiou P, Katsimbri P, Papadavid E (2020) Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis. Can J Cardiol 36(1):100–111. https://doi.org/10.1016/j.cjca.2019.06.021CrossRefPubMed

28.

Xie F, Yun H, Levitan EB, Muntner P, Curtis JR (2019) Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 71(8):1004–1018. https://doi.org/10.1002/acr.23737CrossRefPubMed

29.

Wooten MD, Reddy GV, Johnson RD (2000) Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J 72(12):517–519PubMed

30.

de’ Clari F, Salani I, Safwan E, Giannacco A (2002) Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation 105(21). https://doi.org/10.1161/01.cir.0000017216.41471.df

31.

Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A (2004) Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 22(3):328–330PubMed

32.

Boyer JF, Jamard B, El Mahou S, Laroche M, Mazières B, Cantagrel A, Constantin A (2009) New-onset acute heart failure and ventricular arrhythmia in a patient treated with adalimumab. Joint Bone Spine 76(3):311–313. https://doi.org/10.1016/j.jbspin.2008.08.010CrossRef

33.

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58(4):964–975. https://doi.org/10.1002/art.23383CrossRefPubMed

34.

Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM (2007) Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology(Oxford) 46(11):1688–1693. https://doi.org/10.1093/rheumatology/kem212CrossRefPubMed

35.

Lazzerini PE, Acampa M, Hammoud M, Maffei S, Capecchi PL, Selvi E, Bisogno S, Guideri F, Galeazzi M, Pasini FL (2008) Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol 35(10):1958–1965PubMed

36.

Singh M, Diwan MM, Patel KC (2009) A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J 2:147. https://doi.org/10.1186/1757-1626-2-147CrossRefPubMedPubMedCentral

37.

Adamson R, Yazici Y, Katz ES, Greisman SG, Steiger D (2013) Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis. J Clin Rheumatol 19(7):386–389. https://doi.org/10.1097/RHU.0b013e3182a701cbCrossRefPubMed

38.

Nakamura Y, Izumi C, Nakagawa Y, Hatta K (2012) A case of effusive-constrictive pericarditis accompanying rheumatoid arthritis: the possibility of adverse effect of TNF-inhibitor therapy. J Cardiol Cases 7(1). https://doi.org/10.1016/j.jccase.2012.08.007

39.

Morgan CL, Emery P, Porter D, Reynolds A, Young A, Boyd H, Poole CD, Currie CJ (2014) Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 53(1):186–194. https://doi.org/10.1093/rheumatology/ket333CrossRefPubMed

40.

Menter A, Thaçi D, Wu JJ, Abramovits W, Kerdel F, Arikan D, Guo D, Ganguli A, Bereswill M, Camez A, Valdecantos WC (2017) Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb) 7(3):365–381. https://doi.org/10.1007/s13555-017-0198-xCrossRefPubMed

41.

Generali E, Carrara G, Selmi C, Verstappen SMM, Zambon A, Bortoluzzi A, Silvagni E, Scirè CA (2018) Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. Clin Exp Rheumatol 36(2):310–313PubMed

42.

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M (2018) One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther 20(1):2. https://doi.org/10.1186/s13075-017-1496-5CrossRefPubMedPubMedCentral

43.

Lazarewicz K, Shaw S, Haque S (2018) Certolizumab pegol-induced heart failure. J Clin Rheumatol 24(1):55–56. https://doi.org/10.1097/RHU.0000000000000627CrossRefPubMed

44.

Generali E, Carrara G, Kallikourdis M, Condorelli G, Bortoluzzi A, Scirè CA, Selmi C (2019) Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int 39(2):239–243. https://doi.org/10.1007/s00296-018-4196-9CrossRefPubMed

45.

Soucy-Giguere MC, Charbonneau É, Cinq Mars A, Dubois M, Sénéchal M (2019) Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor. Anatol J Cardiol 22(1):46–48. https://doi.org/10.14744/AnatolJCardiol.2019.67124CrossRefPubMedPubMedCentral

46.

Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 72(1):31–40. https://doi.org/10.1002/art.41095CrossRefPubMed

47.

Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD (2020) Long-term, real-world safety of adalimumab in rheumatoid arthritis: analysis of a prospective US-based registry. J Rheumatol 47(7):959–967. https://doi.org/10.3899/jrheum.190260CrossRefPubMed

48.

Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM, BADBIR Study Group (2020) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol 34(4):769–778. https://doi.org/10.1111/jdv.16018CrossRefPubMed

49.

Burmester GR, Winthrop K, Blanco R, Nash P, Goupille P, Azevedo VF, Salvarani C, Rubbert-Roth A, Lesser E, Lippe R, Lertratanakul A, Mccaskill RM, Liu J, Ruderman EM (2022) Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials. Rheumatol Ther 9(2):521–539. https://doi.org/10.1007/s40744-021-00410-zCrossRefPubMed

50.

Ngoufack C, Semerano L, Podglajen I, Bruneval P, Meune C, Valeyre D, Dhote R, Boissier MC (2021) Saidenberg-Kermanac’h N. Mitral valve granulomatosis: a paradoxical reaction complicating etanercept treatment in rheumatoid arthritis. A case report. Joint Bone Spine 88(4):105183. https://doi.org/10.1016/j.jbspin.2021.105183CrossRefPubMed

51.

Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E (2023) Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis 82(2):182–188. https://doi.org/10.1136/ard-2022-222824CrossRefPubMed

Titel: New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review
verfasst von: Sophie Mavrogeni
Evdoxia Sapountzi
Kyveli Chiotopoulou
Lampros Fotis
Publikationsdatum: 01.01.2025
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 1/2025
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-024-05750-x

Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study

Observational Research

Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study

Open Access
Observational Research

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review

Review

Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study

Observational Research

Spontaneously regressing mass-like soft tissue involvement in a child with chronic non-bacterial osteomyelitis: case-based review

Case Based Review

Fatigue patterns surrounding biologic disease-modifying antirheumatic drug injection in patients with an inflammatory rheumatic disease: an ecological momentary assessment study

Open Access
Patient Opinion

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Therapiestopp bei älteren MS-Kranken kann sich lohnen

17.04.2025
AAN-Jahrestagung 2025
Nachrichten

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Dank Nasenspray seltener in die Notaufnahme

17.04.2025
Supraventrikuläre Tachykardien
Nachrichten

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

17.04.2025
Ablationstherapie
Nachrichten

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review

Abstract

Weitere Artikel der Ausgabe 1/2025

Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study

Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review

Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study

Spontaneously regressing mass-like soft tissue involvement in a child with chronic non-bacterial osteomyelitis: case-based review

Fatigue patterns surrounding biologic disease-modifying antirheumatic drug injection in patients with an inflammatory rheumatic disease: an ecological momentary assessment study

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Dank Nasenspray seltener in die Notaufnahme

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten